Over the last 12 months, Regeneron Pharmaceuticals insiders reported no purchases and 25 sales totaling $64.6M across SEC Form 4 filings. 72% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Decision | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | SING GEORGE LD | ▼ Sale | Discretionaryopen market | 2,000 | $958.97 | $1.9M | -8% | 4 tranches |
| Nov 17, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 5,011 | $957.76 | $4.8M | -9.7% | 16 tranches |
| Nov 16, 2026 | McCourt MarionEVP Commercial · O | ▼ Sale | Non-discretionary10b5-1 plan | 566 | $960.25 | $544K | -5.2% | 13 tranches |
| Nov 4, 2026 | Pitofsky JasonSVP Controller · O | ▼ Sale | Discretionaryexercise and sell | 179 | $950.76 | $170K | -100% | indirect |
| Nov 4, 2026 | Pitofsky JasonSVP Controller · O | ▼ Sale | Discretionaryexercise and sell | 3,883 | $941.79 | $3.7M | -47.6% | 7 tranches |
| Nov 3, 2026 | Zoghbi Huda YD | ▼ Sale | Discretionaryexercise and sell | 7,439 | $970.46 | $7.2M | -81.4% | 2 tranches |
| Nov 2, 2026 | SING GEORGE LD | ▼ Sale | Discretionaryopen market | 21,129 | $964.38 | $20.4M | -45.7% | 9 tranches |
| Nov 2, 2026 | POON CHRISTINE AD | ▼ Sale | Discretionaryexercise and sell | 7,830 | $969.09 | $7.6M | -60% | 6 tranches |
| Nov 2, 2026 | LAROSA JOSEPH JEVP General Counsel and Secret · O | ▼ Sale | Discretionaryexercise and sell | 4,466 | $965.49 | $4.3M | -10.3% | 2 tranches |
| Oct 30, 2026 | Guarini KathrynD | ▼ Sale | Non-discretionary10b5-1 plan | 400 | $900 | $360K | -39.9% | — |
| Oct 30, 2026 | BROWN MICHAEL SD | ▼ Sale | Non-discretionary10b5-1 plan | 1,929 | $875 | $1.7M | -58.3% | — |
| Oct 30, 2026 | McCourt MarionEVP Commercial · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,132 | $869.43 | $984K | -9.4% | — |
| Oct 14, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 4,147 | $772.7 | $3.2M | -8% | 27 tranches |
| Sep 3, 2026 | McCourt MarionEVP Commercial · O | ▼ Sale | Non-discretionary10b5-1 plan | 2,346 | $853.56 | $2.0M | -16.3% | 2 tranches |
| Sep 2, 2026 | Guarini KathrynD | ▼ Sale | Non-discretionary10b5-1 plan | 400 | $850 | $340K | -39.9% | — |
| Aug 10, 2026 | Guarini KathrynD | ▼ Sale | Non-discretionary10b5-1 plan | 400 | $800 | $320K | -39.9% | — |
| Aug 10, 2026 | Zoghbi Huda YD | ▼ Sale | Non-discretionary10b5-1 plan | 800 | $800 | $640K | -32% | — |
| Jul 2, 2026 | RYAN ARTHUR FD | ▼ Sale | Non-discretionary10b5-1 plan | 200 | $650.15 | $130K | -1.1% | — |
| May 1, 2026 | RYAN ARTHUR FD | ▼ Sale | Non-discretionary10b5-1 plan | 100 | $705.24 | $71K | -0.6% | 12 tranches |
| Apr 1, 2026 | RYAN ARTHUR FD | ▼ Sale | Non-discretionary10b5-1 plan | 100 | $777.27 | $78K | -0.6% | 9 tranches |
| Mar 2, 2026 | RYAN ARTHUR FD | ▼ Sale | Non-discretionary10b5-1 plan | 100 | $785.5 | $79K | -0.6% | 13 tranches |
| Feb 19, 2026 | Zoghbi Huda YD | ▼ Sale | Non-discretionary10b5-1 plan | 1,638 | $781.33 | $1.3M | -49% | 11 tranches |
| Feb 9, 2026 | Pitofsky JasonSVP Controller · O | ▼ Sale | Non-discretionary10b5-1 plan | 2,036 | $778.52 | $1.6M | -32.3% | 11 tranches |
| Feb 9, 2026 | RYAN ARTHUR FD | ▼ Sale | Non-discretionary10b5-1 plan | 100 | $778.53 | $78K | -0.6% | 13 tranches |
| Jan 7, 2026 | Bassler Bonnie LD | ▼ Sale | Non-discretionary10b5-1 plan | 1,500 | $800 | $1.2M | -46.8% | — |
| Nov 20, 2025 | Bassler Bonnie LD | ▼ Sale | Non-discretionary10b5-1 plan | 760 | $750 | $570K | -32.9% | — |
| Nov 7, 2025 | Pitofsky JasonVP Controller · O | ▼ Sale | Discretionaryopen market | 431 | $651.43 | $281K | -9.2% | — |
| Oct 29, 2025 | POON CHRISTINE AD | ▼ Sale | Discretionaryexercise and sell | 6,500 | $654.27 | $4.3M | -73.4% | 6 tranches |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Regeneron Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $REGN feed.